Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical ICPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | NR7 | Range Contraction | 0.00% |
| Sep 20 | Multiple of Ten Bearish | Other | 0.00% |
| Sep 20 | Inside Day | Range Contraction | 0.00% |
| Sep 19 | Upper Bollinger Band Walk | Strength | -0.43% |
| Sep 19 | Multiple of Ten Bearish | Other | -0.43% |
| Sep 19 | Upper Bollinger Band Touch | Strength | -0.43% |
| Sep 18 | New 52 Week Closing High | Bullish | -1.45% |
| Sep 18 | Pocket Pivot | Bullish Swing Setup | -1.45% |
| Sep 18 | Upper Bollinger Band Walk | Strength | -1.45% |
| Sep 18 | Multiple of Ten Bullish | Other | -1.45% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-07-30
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ICPT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 124.4 |
| 52 Week Low | 51.05 |
| Average Volume | 472,757 |
| 200-Day Moving Average | 77.056 |
| 50-Day Moving Average | 105.8112 |
| 20-Day Moving Average | 113.6915 |
| 10-Day Moving Average | 117.329 |
| Average True Range | 3.9397 |
| ADX | 36.23 |
| +DI | 29.387 |
| -DI | 8.2033 |
| Chandelier Exit (Long, 3 ATRs ) | 112.5809 |
| Chandelier Exit (Short, 3 ATRs ) | 114.8991 |
| Upper Bollinger Band | 122.3663 |
| Lower Bollinger Band | 105.0167 |
| Percent B (%b) | 0.8 |
| BandWidth | 15.260244 |
| MACD Line | 4.0859 |
| MACD Signal Line | 3.882 |
| MACD Histogram | 0.2039 |
| Fundamentals | Value |
|---|---|
| Market Cap | 2.98 Billion |
| Num Shares | 25.1 Million |
| EPS | -15.49 |
| Price-to-Earnings (P/E) Ratio | -7.67 |
| Price-to-Sales | 20.99 |
| Price-to-Book | 8.77 |
| PEG Ratio | -0.61 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 121.97 | ||||
| Resistance 3 (R3) | 122.27 | 121.52 | 121.45 | ||
| Resistance 2 (R2) | 121.52 | 120.73 | 121.38 | 121.28 | |
| Resistance 1 (R1) | 120.19 | 120.24 | 119.82 | 119.89 | 121.10 |
| Pivot Point | 119.44 | 119.44 | 119.26 | 119.30 | 119.44 |
| Support 1 (S1) | 118.11 | 118.65 | 117.74 | 117.81 | 116.60 |
| Support 2 (S2) | 117.36 | 118.16 | 117.22 | 116.42 | |
| Support 3 (S3) | 116.03 | 117.36 | 116.25 | ||
| Support 4 (S4) | 115.73 |
